2016


To access this material please log in or register

Register Authorize
2016/№2

Impaired kidney function in patients with chronic heart failure with preserved ejection fraction

Kuzmin O. B., Zezha V. V., Belyanin V. V., Landar L. N.
State Budgetary Institution of Higher Professional Education, “Orenburg State Medical University” of the RF Ministry of Health Care, Sovetskaya 6, Orenburg 460000

Keywords: CHF, preserved ejection fraction, kidneys function

DOI: 10.18087/rhfj.2016.2.2209

The review present results of clinical studies focusing on evaluation of the mechanism for development and progression of chronic kidney disease (CKD) in CHF patients with preserved EF (CHF-PEF). Authors discussed prognostic value of CHF-PEF and relationship with clinical efficacy of RAS inhibitors and mineralocorticoid receptor antagonists.
  1. Cheng RK, Cox M, Neely ML, Heidenreich PA, Bhatt DL, Eapen ZJ et al. Outcomes in patients with heart failure with preserved, borderline and reduced ejection fraction in Medicare population. Am Heart J. 2014 Nov;168 (5):721–30.
  2. Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Т., Фомин И. В., Бадин Ю. В., Поляков Д. С. и др. Истинная распространенность ХСН в Европейской части Российской федерации (исследование ЭПОХА, госпитальный этап). Журнал СН. 2011;12 (2):63–8 [Belenkov Yu. N., Mareev V. Yu., Ageev F. T., Fomin I. V., Badin Yu. V., Polyakov D. S. i dr. Istinnaya rasprostranennost` XSN v Evropejskoj chasti Rossijskoj federaczii (issledovanie E`POXA, gospital`ny`j e`tap). Zhurnal Serdechnaya Nedostatochnost`. 2011;12 (2):63–8].
  3. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006 Oct;27 (19):2338–45.
  4. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008 Dec 4;359 (23):2456–67.
  5. Shah SJ, Heitner JF, Sweitzer NK, Anand IS, Kim HY, Harty B et al. Baseline characteristics of patients in the treatment of preserve cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail. 2013 Mar;6 (2):184–92.
  6. Моисеев В. С., Мухин Н. А., Смирнов А. В., Кобалава Ж. Д., Бобкова И. Н., Виллевальде С. В. и др. Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардио-нефропротекции. Клиническая фармакология и терапия. 2014;23 (3):4–27 [Moiseev V. S., Muxin N. A., Smirnov A. V., Kobalava Zh. D., Bobkova I. N., Villeval`de S. V. i dr. Serdechno-sosudisty`j risk i xronicheskaya bolezn` pochek: strategii kardio-nefroprotekczii. Klinicheskaya farmakologiya i terapiya. 2014;23 (3):4–27].
  7. Miura M, Shiba N, Nochioka K, Takada T, Takahashi J, Kohno H et al. Urinary albumin excretion in heart failure with preserved ejection fraction: an interim analysis of CHART 2 study. Eur J Heart Fail. 2012 Apr;14 (4):367–76.
  8. Weinberger MH. Salt sensitivity of blood pressure in humans. Hypertension. 1996 Mar;27 (3 Pt 2):481–90.
  9. van Veldhuisen DJ, Linssen GC, Jaarsma T, van Gilst WH, Hoes AW, Tijssen JG et al. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol. 2013 Apr 9;61 (14):1498–506.
  10. Guder G, Bauersachs J, Frantz S, Weismann D, Allolio B, Ertl G et al. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation. 2007 Apr 3;115 (13):1754–61.
  11. Edelmann F, Tomaschitz A, Wachter R, Gelbrich G, Knoke M, Dungen HD et al. Serum aldosterone and its relation to left ventricular structure and geometry in patients with preserved left ventricular ejection fraction. Eur Heart J. 2012 Jan;33 (2):203–12.
  12. Kitzman DW, Little WC, Brubaker PH, Anderson RT, Hundley WG, Marburger CT et al. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA. 2002 Nov 6;288 (17):2144–50.
  13. Yusuf S, Pfeffer MA, Swedberg K, Grander CB, Held P, McMurray JJ et al. Effect of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet. 2003 Sep 6;363 (9386):777–81.
  14. Vogel MW, Slusser JP, Hodge DO, Chen HH. The natural history of preclinical diastolic dysfunction: a population based study. Circ Heart Fail. 2012 Mar 1;5 (2):144–51.
  15. de Souza SB, Rocha JA, Cuoco MA, Guerra GM, Ferreira-Filho JC, Borile S et al. High muscle sympathetic nerve activity is associated with left ventricular dysfunction in treated hypertensive patients. Am J Hypertens. 2013 Jul;26 (7):912–7.
  16. Guglin M, Rivero A, Matar F, Garcia M. Renal dysfunction in heart failure is due to congestive but not low output. Clin Cardiol. 2011 Feb;34 (2):113–6.
  17. Poetzl G, Ess M, Von der Heidt A, Rudnicki M, Frick M, Ulmer H. Concomitant renal and hepatic dysfunctions in chronic heart failure: clinical implications and prognostic significance. Eur J Intern Med. 2013 Mar;24 (2):177–82.
  18. Hemmi S, Matsumoto N, Jike T, Obana Y, Nakanishi Y, Soma M, Hemmi A. Proximal tubule morphology in rats with renal congestion: a study involving the vivo cryotechnique. Med Mol Morphol. 2015 Jun;48 (2):92–103.
  19. Кузьмин О. Б. Хроническая болезнь почек: механизмы развития и прогрессирования гипоксического гломерулосклероза и тубулоинтерстициального фиброза. Нефрология. 2015;19 (4):9–16 [Kuz`min O. B. Xronicheskaya bolezn` pochek: mexanizmy` razvitiya i progressirovaniya gipoksicheskogo glomeruloskleroza i tubulointersticzial`nogo fibroza. Nefrologiya. 2015;19 (4):9–16].
  20. Tanaka M, Yoshida H, Furuhashi M, Togashi N, Koyama M, Yamamoto S et al. Deterioration of renal function by chronic heart failure is associated with congestion and oxidative stress in tubulointerstitium. Intern Med. 2011;50 (23):2877–87.
  21. Ahmed A, Rich MW, Sander PW, Perry GJ, Bakris GL, Zile MR et al. Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. Am J Cardiol. 2007 Feb 1;99 (3):393–8.
  22. Gori M, Senni M, Gupta DK, Charytan DM, Kraigher-Krainer E, Pieske B et al. Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. Eur Heart J. 2014;35 (48):3442–51.
  23. Casado J, Montero M, Forniga F, Carrera M, Urrutia A, Arevalo JC, Perez-Calvo JI. Clinical characteristic and prognostic influence of renal dysfunction in heart failure patients with preserved ejection fraction. Eur J Intern Med. 2013 Oct;24 (7):677–83.
  24. Smith DH, Thorp ML, Gurwitz JH, McManus DD, Goldberg RJ, Allen LA et al. Chronic kidney disease and outcomes in heart failure with preserved versus reduced ejection fraction: the cardiovascular research network PRESERVE study. Circ Cardiovasc Qual Outcomes. 2013 May 1;6 (3):333–42.
  25. Mujib M, Patel K, Fonarow GC, Kitzman DW, Zhang Y, Aban IB et al. Angiotensin-converting enzyme inhibitors and outcomes in heart failure and preserved ejection fraction. Am J Med. 2013 May;126 (5):401–10.
  26. Lund LH, Benson L, Dahlstrom U, Edner M. Association between use renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. JAMA. 2012 Nov 28;308 (20):2108–17.
  27. Ahmed A, Rich MW, Zile M, Sanders PW, Patel K, Zhang Y et al. Renin-angiotensin inhibition in diastolic heart failure and chronic kidney disease. Am J Med. 2013 Feb;126 (2):150–61.
  28. Edelmann F, Wacther R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA. 2013 Feb 27;309 (8):781–91.
  29. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014 Apr 10;370 (15):1383–92.
Kuzmin O. B., Zezha V. V., Belyanin V. V., Landar L. N. Impaired kidney function in patients with chronic heart failure with preserved ejection fraction. Russian Heart Failure Journal. 2016;17 (2):137–143

To access this material please log in or register

Register Authorize
Ru En